Media
[NEWS] Hua Medicine and DKSH Hong Kong Expand Strategic Partnership to Advance Innovative Diabetes Solutions
June 29, 2026 – Shanghai, China
Hua Medicine and DKSH Hong Kong announced the expansion of their strategic partnership to accelerate patient access to innovative drug therapies in Hong Kong. The partnership brings together Hua Medicine's expertise in metabolic disease drug development and DKSH's integrated market expansion capabilities to deliver long-term value and meaningful healthcare impact across the region.
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552), is a leading innovative pharmaceutical company dedicated to the discovery and development of treatments for metabolic diseases. It announced today that its wholly owned subsidiary, Hua Medicine Technology (Hong Kong) Limited, will further strengthen its collaboration with DKSH's Business Healthcare Unit to provide comprehensive go-to-market and market access support for its diabetes portfolio, with the shared goal of promoting regional healthcare accessibility and improved outcomes for diabetes patients.
Under this expanded agreement, DKSH Healthcare will leverage its end-to-end commercialization platform to support accelerated product launch, market uptake, and broad patient access across Hong Kong. The collaboration will help Hua Medicine scale efficiently in Hong Kong and bring high-quality, innovative diabetes solutions to a broader patient population.
Dr. Li Chen, Founder and CEO of Hua Medicine, said: "We are delighted to collaborate with DKSH. With its extensive experience in Hong Kong and the Greater Bay Area, strong market access and go-to-market capabilities, and robust distribution network, DKSH will help accelerate the market launch and adoption of our core product. This innovative therapy, which restores glucose homeostasis, can reach local patients with type 2 diabetes more quickly. We believe DKSH will be a trusted strategic partner, supporting greater accessibility and benefiting more patients."
Wai Ting Fong, Vice President, Healthcare, Hong Kong & Macau at DKSH, said: "DKSH is honored to partner with Hua Medicine. This collaboration further strengthens our value proposition in the healthcare sector and reflects our commitment to delivering high-quality, sustainable growth solutions to our partners. With our experienced team and strong local market expertise, we look forward to supporting Hua Medicine’s long-term success while enhancing patient access to better healthcare services."
DKSH's Business Unit Healthcare is uniquely positioned to connect innovation with access, bringing together its integrated end-to-end go-to-market platform, deep local expertise, and patient-centric performance culture to deliver impact at scale. By combining strong partnerships, disciplined execution, and a shared commitment to patients, DKSH will continue to simplify complexity, unlock growth, and expand access to healthcare solutions across Asia and beyond.
About Hua Medicine
Hua Medicine (the "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.
About DKSH
For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,580 specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025. www.dksh.com/hec
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
